NEW YORK CITY (dpa-AFX) - Labcorp (LH) announced the FDA has approved its
nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic to determine patient
eligibility for treatment with BEQVEZ, Pfizer's recently FDA-approved hemophilia
B gene therapy. The results from the nAbCyte test will be reported qualitatively
as negative or positive. A negative test result indicates that an individual
with moderate to severe hemophilia B can be considered for BEQVEZ therapy.

Sonal Bhatia, Head of U.S. Specialty Care Medical Affairs, Pfizer, said: 'We
believe this companion diagnostic is an important tool for evaluating patients
who may be suitable for gene therapy as the treatment paradigm advances with the
introduction of gene therapies like BEQVEZ.'

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX